Role of Empagliflozin and Linagliptin Combination in Diabetic Kidney Disease

Chronic kidney disease (CKD) is a common comorbidity in type 2 diabetes mellitus (T2DM). It has been documented that CKD is associated with an increased risk of CVD and this further increases the mortality rate in T2DM by 2-3-fold. The current need is of a comprehensive approach to T2DM with concomitant renal disease. Scientific literature recommends early use of combination therapy in T2DM patients with a high risk of renal impairment. Considering the recent guidelines and published data on renal benefits with empagliflozin and linagliptin, combination therapy with these two agents may be a promising option in preventing and delaying the progression of renal impairment in T2DM patients. This review highlights the clinical evidence and the possible mechanisms for renal benefits with empagliflozin and linagliptin.